{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:21:21Z","timestamp":1787016081994,"version":"build-2736575974"},"reference-count":24,"publisher":"Wiley","issue":"S3","license":[{"start":{"date-parts":[[2018,12,7]],"date-time":"2018-12-07T00:00:00Z","timestamp":1544140800000},"content-version":"vor","delay-in-days":6,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Transfusion"],"published-print":{"date-parts":[[2018,12]]},"abstract":"<jats:p>Wild poliovirus (WPV) is nearing eradication, and only three countries have never interrupted WPV transmission (Pakistan, Afghanistan, and Nigeria). WPV2 was last detected in 1999, and it was declared eradicated in 2015. WPV3 has not been detected since 2012. Since 2016, WPV1 has been detected in only two countries (Afghanistan and Pakistan), with only 22 cases reported in 2017 and 12 cases reported in 2018 (as of July 10). Because of WPV2 eradication and the risk of emergence of type 2 vaccine\u2013derived polioviruses from continued use of trivalent oral polio vaccine (OPV), trivalent OPV was replaced by bivalent OPV (types 1 and 3) in a globally coordinated effort in 2016. WPV2 eradication and trivalent OPV cessation also mean that breach of containment in a facility working with type 2 poliovirus is now a major risk to reseed type 2 circulation in the community. As a result, the World Health Organization has developed a \u201cGlobal Action Plan to minimize poliovirus facility\u2010associated risk after type\u2010specific eradication of wild polioviruses and sequential cessation of oral polio vaccine use.\u201d Because poliovirus has long been used as a standard for qualification of intravenous immunoglobulin, disinfectant products, and sanitation methods, poliovirus containment has implications far beyond poliovirus laboratories.<\/jats:p>","DOI":"10.1111\/trf.15018","type":"journal-article","created":{"date-parts":[[2018,12,7]],"date-time":"2018-12-07T09:18:50Z","timestamp":1544174330000},"page":"3078-3083","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Progress of polio eradication and containment requirements after eradication"],"prefix":"10.1111","volume":"58","author":[{"given":"M. Steven","family":"Oberste","sequence":"first","affiliation":[{"name":"Division of Viral Diseases, Centers for Disease Control and Prevention  Atlanta Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,12,7]]},"reference":[{"key":"e_1_2_6_2_1","first-page":"657","volume-title":"Red Book: 2018 report of the Committee on Infectious Diseases","author":"American Academy of Pediatrics. Poliovirus infections","year":"2018"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-1-4557-0090-5.00035-5"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/175.Supplement_1.S176"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6714a3"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6718a4"},{"key":"e_1_2_6_7_1","unstructured":"Global Polio Eradication Initiative. Global Polio Eradication Initiative Home 2018. Available from:http:\/\/www.polioeradication.org."},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiu295"},{"key":"e_1_2_6_9_1","volume-title":"14th meeting of the Global Commission for the Certification of Poliomyelitis Eradication (GCC) [monograph on the internet]","author":"Global Commission for the Certification of Poliomyelitis Eradication","year":"2015"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-1-4557-0090-5.00034-3"},{"key":"e_1_2_6_11_1","unstructured":"World Health Organization. Guidelines for the safe production and quality control of inactivated poliomyelitis vaccine manufactured from wild polioviruses (Addendum 2003 to the Recommendations for the Production and Quality Control of Poliomyelitis Vaccine (Inactivated) WHO Technical Report Series No. 926. Geneva 2004. [accessed 2018 Sep 10] Available from:http:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/43049\/WHO_TRS_926.pdf;jsessionid=5261FCA6BB47B3626C6EB058F36544FC?sequence=1"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01031-17"},{"key":"e_1_2_6_13_1","volume-title":"Vaccine\u2010associated paralytic polio (VAPP) and vaccine\u2010derived poliovirus (VDPV) [monograph on the internet]","author":"World Health Organization","year":"2015"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.401"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01103"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1005114"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiu043"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6535a3"},{"key":"e_1_2_6_19_1","volume-title":"WHO Global Action Plan to minimize poliovirus facility\u2010associated risk after type\u2010specific eradication of wild polioviruses and sequential cessation of oral polio vaccine use","author":"World Health Organization","year":"2015"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2017.22.21.30542"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2016.21.11.30169"},{"key":"e_1_2_6_22_1","volume-title":"15th Meeting of the SAGE Polio Working Group: Conclusions and Recommendations, Note for the Record [monograph on the internet]","author":"World Health Organization","year":"2018"},{"key":"e_1_2_6_23_1","unstructured":"United States Food and Drug Administration. Code of Federal Regulations Title 21 Part 640 Subpart J Section 640.104: Additional standards for human blood and blood products immune globulin (human) potency 2017. [accessed 2018 Jun 27] Available from:https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfcfr\/CFRSearch.cfm?fr=640.104"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-3292-4_8"},{"key":"e_1_2_6_25_1","unstructured":"United States Environmental Protection Agency. Environmental Regulations and Technology: Control of Pathogens and Vector Attraction in Sewage Sludge 2003. [accessed 2018 Jun 27] Available from:https:\/\/www.epa.gov\/sites\/production\/files\/2015-04\/documents\/control_of_pathogens_and_vector_attraction_in_sewage_sludge_july_2003.pdf"}],"container-title":["Transfusion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Ftrf.15018","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/trf.15018","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/trf.15018","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/trf.15018","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T14:33:51Z","timestamp":1694615631000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/trf.15018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":24,"journal-issue":{"issue":"S3","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["10.1111\/trf.15018"],"URL":"https:\/\/doi.org\/10.1111\/trf.15018","archive":["Portico"],"relation":{},"ISSN":["0041-1132","1537-2995"],"issn-type":[{"value":"0041-1132","type":"print"},{"value":"1537-2995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"2018-07-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-10-05","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-12-07","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}